These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14532826)

  • 1. Re: Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer.
    Pitts WR
    J Urol; 2003 Nov; 170(5):1954; author reply 1954-5. PubMed ID: 14532826
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer.
    Kikuchi E; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    J Urol; 2003 Feb; 169(2):730-4. PubMed ID: 12544353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation.
    Sonnemann J; Gekeler V; Sagrauske A; Müller C; Hofmann HP; Beck JF
    Int J Oncol; 2004 Oct; 25(4):1171-81. PubMed ID: 15375570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer.
    Baltogiannis D; Charalabopoulos K; Giannakopoulos X; Karakosta A; Sofikitis N
    Exp Oncol; 2005 Jun; 27(2):91-3. PubMed ID: 15995623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.
    Pu YS; Hour TC; Chuang SE; Cheng AL; Lai MK; Kuo ML
    Prostate; 2004 Jul; 60(2):120-9. PubMed ID: 15162378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
    Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
    Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
    Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
    Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 10. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel.
    Sonnemann J; Gekeler V; Ahlbrecht K; Brischwein K; Liu C; Bader P; Müller C; Niethammer D; Beck JF
    Cancer Lett; 2004 Jun; 209(2):177-85. PubMed ID: 15159020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing.
    Husbeck B; Peehl DM; Knox SJ
    Free Radic Biol Med; 2005 Jan; 38(1):50-7. PubMed ID: 15589371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
    Rashmi R; Kumar S; Karunagaran D
    Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 19. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.